

BUILDING A BETTER FUTURE

GROWING LONG-TERM VALUE

2021 First Quarter Results Conference Call

May 13, 2021



NON-GAAP MEASURES

"EBITDA", "Adjusted EBITDA", "net operating income" (NOI), "funds from operations" (FFO), and "adjusted funds from operations" (AFFO) are non-GAAP measures and do not have standardized meanings prescribed by GAAP. See "Non-GAAP Measures" in Extendicare's most recent MD&A.

FORWARD-LOOKING STATEMENTS

This presentation contains certain forward-looking statements within the meaning of applicable Canadian securities laws ("forward-looking statements" or "forward-looking information"). Statements other than statements of historical fact contained in this presentation may be forward-looking statements, including, without limitation, management's expectations, intentions and beliefs concerning anticipated future events, results, circumstances, economic performance or expectations with respect to the Company, including, without limitation: statements regarding its business operations, business strategy, growth strategy, results of operations and financial condition, including anticipated timelines, costs and financial returns in respect of development projects, and in particular statements in respect of the impact of COVID-19, the impact of COVID-19, the availability of various government programs and financial assistance announced in respect of COVID-19, the impact of COVID-19 on the Company's operating costs, staffing, procurement, occupancy levels (primarily in its retirement communities) and volumes in its home health care business, the impact on the capital and credit markets and the Company's ability to access the credit markets can often be identified by the expressions "anticipate", "estimate", "expect", "intend", "objective", "plan", "project", "will" or other similar expressions or the negative thereof. These forward-looking statements reflect the Company's current expectations regarding future results, performance or achievements and are based upon information currently available to the Company's current expectations regarding future results, ereasonable. Actual results and developments may differ materially from results and developments discussed in the forward-looking statements, as they are subject to a number of risks and uncertainties.

Although forward-looking statements are based upon estimates and assumptions that the Company believes are reasonable based upon information currently available, these statements are not representations or guarantees of future results, performance or achievements of the Company and are inherently subject to significant business, economic and competitive uncertainties and contingencies and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Extendicare to differ materially from those expressed or implied in the statements.

In particular, risks and uncertainties related to the effects of COVID-19 on Extendicare include: the length, spread and severity of the pandemic; the nature and extent of the measures taken by all levels of governments and public health officials, both short and long term, in response to COVID-19; domestic and global credit and capital markets; the Company's ability to access capital on favourable terms or at all due to the potential for reduced revenue and increased operating expenses as a result of COVID-19; the availability of insurance on favourable terms; litigation and/or regulatory proceedings against or involving the Company, regardless of merit; the health and safety of the Company's employees and its residents and clients; and domestic and global supply chains, particularly in respect of personal protective equipment. Given the evolving circumstances surrounding COVID-19, it is difficult to predict how significant the adverse impact will be on the global and domestic economy and the business operations and financial position of Extendicare. For further information on the risks, uncertainties and assumptions that could cause Extendicare's actual results to differ from current expectations, refer to "Risk Factors" in Extendicare's Annual Information Form and "Forward Looking-Statements" in Extendicare's website at www.extendicare.com.

Readers should not place undue reliance on such forward-looking statements and assumptions as management cannot provide assurance that actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. The forwardlooking statements speak only as of the date of this presentation. Except as required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

COVID-19 UPDATE

- Safety of our residents, clients and staff remains our top priority
- Vaccination campaign is well advanced:
 - Residents: 90% in LTC and 86% in Esprit fully vaccinated
 - Staff: 74% in LTC and 67% in Esprit vaccinated with 1st dose
 - ParaMed campaign well under way
- Vaccinations significantly reducing outbreaks; only 2 active resident cases as of May 11, 2021
- Deployed point-of-care rapid testing in all LTC homes in Q1
- Added 1,000+ new frontline caregivers to our LTC homes over the past year
- Additional COVID funding from governments and provincial health authorities

Vaccines and point-of-care testing critical to our ability to protect residents, clients and staff



2021 FIRST QUARTER HIGHLIGHTS

- Pandemic costs exceeded funding by \$2.3M in Q1, higher costs in the quarter offset by \$18.8M in LTC COVID funding related to costs incurred in 2020⁽¹⁾
- Volatility in results expected to continue due to timing of COVID costs and related funding
- Home health care volumes and margins recovering but remain below pre-COVID levels
- ParaMed NOI benefiting from lower back-office costs after completion of new platform
- Retirement living occupancy ended Q1 in line with Q4 2020
- SGP customer base grew 11.3% from last year
- Broke ground on our second LTC redevelopment project

Investing in people, training and technology



LONG-TERM CARE – REDEVELOPMENT ADVANCING

- Targeting six projects under construction by end of 2022 and an additional three projects in 2023, representing an estimated total investment of \$500M
- Kingston 192-bed home broke ground last month to replace a 150-bed Class C home when complete in Q1 2023
- Stittsville 256-bed home in final approval stages to commence construction later this year to replace a Class C home in the Ottawa area
- Subsequent to Q1, secured a \$95.9M construction financing commitment for our Sudbury and Kingston projects

Investing in a better future for seniors




LONG-TERM CARE – COVID-19 DRIVES INCREASED COSTS, ADDITIONAL FUNDING OFFSETS IMPACT

- COVID costs⁽¹⁾ of \$48.1M in Q1, up from \$34.3 in Q4 2020
- COVID funding in Q1 included \$18.8M related to 2020, resulting in net COVID costs of only \$1.1M for LTC in Q1
- Occupancy declined to 82.9% due to pandemic related admission restrictions, but revenue is supported by basic occupancy funding protection
- Ongoing Ontario government support announced in Q1:
 - Basic occupancy protection extended to August 2021
 - Additional \$600M in prevention and containment funding for 2021-22 government fiscal year
- Occupancy is recovering supported by vaccination campaign

Long-term stable revenue base with future growth potential



Average Occupancy




PARAMED – VOLUME AND MARGINS RECOVERING, STAFFING CAPACITY CONTINUES TO WEIGH ON VOLUME

- ADV recovering, but constrained by workforce capacity:
 - Q1 ADV up 1.7% from Q4 2020
 - 4-weeks ending May 2nd up 2.7% from Q1
- Improved back-office efficiencies contributing to NOI margin growth
- Training programs on track to add 600 front-line team members in 2021
- Volume anticipated to increase as pandemic subsides and staffing capacity grows
- Demand has returned to pre-COVID levels and strong fundamental long-term market growth >4%



Home Health Care



Workforce capacity remains the focus to drive improved volume recovery



FINANCIAL REVIEW

Q1 2021



CONSOLIDATED RESULTS

Three months ended March 31, 2021

(\$ millions, except per share amounts)

	Revenue	
Q1 2021 \$322.4	Q1 2020 \$271.8	Change 18.6%
١	NOI and Margin	
Q1 2021 \$40.3 12.5%	Q1 2020 \$30.4 11.2%	Change 32.5% 1 130 bps
Adjuste	d EBITDA and I	Margin
Q1 2021 \$27.7 8.6%	Q1 2020 \$20.1 7.4%	Change 37.7% 120 bps
AFFO a	nd AFFO per Sl	hare ⁽¹⁾
Q1 2021 \$19.5 \$0.22	Q1 2020 \$11.6 \$0.13	Change 68.0% 1

EBITDA and AFFO/Share⁽¹⁾ impact of Select Items


EPITDA impost	Q1 2021	Q1 2020	Change
EBITDA impact: Net COVID Costs ParaMed CEWS	\$(2.3) \$9.7	\$(0.3) \$0.0	\$(2.0) \$9.7
AFFO/Share impact: Net COVID Costs ParaMed CEWS	\$(0.02) \$0.08	Ξ	\$(0.02) \$0.08

Payout ratio of 55% in Q1 2021 compared to 92% in Q1 2020 and 81% FY2020

LONG-TERM CARE

Three month ended March 31, 2021

Revenue		
Q1 2021	\$205.1M	28.0% 🕇
NOI		
Q1 2021	\$16.3M	-11.6%
margin	7.9%	-360 bps
Average O	ccupancy	
Q1 2021	82.9%	-1,410 bps



- Q1 revenue up \$44.9M YoY, primarily from increased COVID-19 funding of \$46.6M
- Q1 NOI down \$2.1M, impacted by:
 - \$0.8M of higher unfunded COVID costs
 - Lower preferred occupancy revenue due to COVID-19
- Q1 NOI margin of 11.0%, excluding net COVID-19 costs
- Basic occupancy funding protection in Ontario extended to August 31, 2021
- Governments continue to support LTC sector with additional COVID-19 response funding; ongoing volatility in matching with expenditures



HOME HEALTH CARE

Three month ended March 31, 2021

Revenue		
Q1 2021	\$97.7M	4.9% 🕇
NOI		
Q1 2021	\$16.0M	269.7%
margin	16.3%	1,170 bps
Average Da	ily Volume (A	ADV)
Q1 2021	24,352	-1.3% 🖊
9.0%	Ol Margin (ex-COVIE 7%	7.3%

or or or or or or or or

- Q1 revenue up \$4.6M, or 4.9%, impacted by:
 - COVID-19 and pandemic pay funding of \$8.8M
 - 1.3% decline in ADV and expiration of B.C. contracts in Q1 2020
- Q1 NOI and margin up to \$16.0M and 16.3%, respectively, reflecting CEWS of \$9.7M and lower back-office costs, partially offset by decline in ADV vs Q1 2020
- Sequential ADV and margin improvements:
 - Q1 ADV up 1.7% from Q4 2020; 4-weeks ending May 2, 2021 up 2.7% compared to Q1
 - Q1 NOI⁽¹⁾ margin 7.3%, up from 4.6% in Q1 2020 and 5.8% in Q4 2020

(1) NOI margins excluding net COVID costs as outlined on Slide 18, CEWS (Q1 2021 \$9.7M; Q3 2020 \$50.8M, Q4 2020 \$40.4M), and Q4 2020 onetime charges of \$6.1M




RETIREMENT LIVING

Three month ended March 31, 2021

Revenue		
Q1 2021	\$12.2M	1.1% 🕇
NOI		
Q1 2021	\$3.4M	-7.1% 📘
margin	28.3%	-250 bps
Average Sta	abilized Occu	pancy
Q1 2021	90.7%	-280 bps
As at Stabil	ized Occupa	ncy
Q1 2021	91.0%	-180 bps

- April 2021 as at occupancy vs. Q1:
 - Stabilized -80 bps (90.2%)
 - Lease-up +160 bps (71.1%)
 - Overall -10 bps (84.5%)

- Q1 revenue up 1.1%, NOI down 7.1% and margin down 250 bps
- Contributions from lease-up were offset by the negative impact of COVID-19 on stabilized occupancy and costs
- Occupancy continues to be impacted by restrictions on in-person tours and move-in protocols
- Average stabilized occupancy holding above 90%; average lease-up occupancy up 130 bps vs. Q1 2020



Stabilized Portfolio Occupancy at Period End

OTHER CANADIAN OPERATIONS

Three month ended March 31, 2021


Revenue		
Q1 2021	\$7.4M	15.0%
NOI		
Q1 2021	\$4.6M	16.4%
margin	61.7%	80 bps
Contract Ser	vices	
Beds	6,359	-3.7%
SGP		
Residents	81,110	11.3%

 Improvement driven by growth in SGP client base of 11.3% and lower costs of travel and business promotion due to COVID restrictions

EXTENDICARE +

assist


Better all together



STRONG FINANCIAL POSITION

As at March 31, 2021

Long-term Debt ⁽¹⁾	Cash		EBITDA interest coverage	Debt to GBV	Weighted average rate
\$573M	\$141M	Q1 2021	5.0x	46.2%	4.3%
		Q4 2020	4.7x	45.9%	4.3%




Strong liquidity position and no scheduled debt maturities until Q1 2022

(1) Includes current portion, reflects 2025 convertible debt at face of \$126.5M and excludes deferred financing costs

(2) Demand constructions loans are reflected as current

COMPELLING GROWTH OPPORTUNITIES ACROSS THE CARE CONTINUUM



B2B: contract & consulting services



THANK YOU









Q1 2021 ESTIMATED COVID-19 REVENUE, OPERATING EXPENSES AND ADMINISTRATIVE COSTS

Three months ended March 31, 2021

	2021					2020
(millions of dollars)	Q1	Q4	Q3	Q2	Q1	Year
Revenue						
Long-term care	47.0	25.6	21.1	17.6	0.4	64.7
Retirement living	-	-	-	-	-	-
Home health care	8.8	6.4	7.6	9.6	-	23.6
Revenue impact	55.8	32.0	28.7	27.2	0.4	88.3
Operating Expenses						
Long-term care	48.1	34.3	27.7	26.2	0.7	88.9
Retirement living	0.1	0.1	0.5	0.5	-	1.1
Home health care	9.0	7.2	7.7	10.0	-	24.9
Operating expenses impact	57.2	41.6	35.9	36.7	0.7	114.9
NOI						
Long-term care	(1.1)	(8.7)	(6.6)	(8.6)	(0.3)	(24.2)
Retirement living	(0.1)	(0.1)	(0.5)	(0.5)	-	(1.1)
Home health care	(0.2)	(0.8)	(0.1)	(0.4)	-	(1.3)
NOI impact	(1.4)	(9.6)	(7.2)	(9.5)	(0.3)	(26.6)
Administrative costs	0.9	0.7	1.6	1.2	-	3.5
Adjusted EBITDA impact	(2.3)	(10.3)	(8.8)	(10.7)	(0.3)	(30.1)

RESULTS – NOI BY DIVISION⁽¹⁾

Three month ended March 31, 2021

(\$ millions)

Long-term	Care NOI and	Margin ⁽¹⁾	Home Healt	h Care NOI ar	nd Margin ⁽¹⁾
Q1 2021 \$17.4 11.0%	Q1 2020 \$18.7 11.7%	Change -7.1% -70 bps	Q1 2021 \$6.5 7.3%	Q1 2020 \$4.3 4.6%	Change 50.5% 1 270 bps
Average Oc	cupancy		Average Dai	ly Volume (A	DV) ⁽²⁾
82.9%	97.0%	-1,410 bps	24,352	24,682	-1.3%
Retirement	Living NOI a	nd Margin ⁽¹⁾	Assist/SGP	NOI and Marg	gin
Retirement Q1 2021 \$3.5 28.9%	Living NOI at Q1 2020 \$3.7 31.0%	nd Margin ⁽¹⁾ Change -5.9% -210 bps	Assist/SGP Q1 2021 \$4.6 61.7%	NOI and Marg Q1 2020 \$3.9 60.9%	change 16.4% 80 bps
Q1 2021 \$3.5 28.9%	Q1 2020 \$3.7	Change -5.9% -210 bps	Q1 2021 \$4.6 61.7%	Q1 2020 \$3.9	Change 16.4% 80 bps

(1) Excludes the impact of COVID-19 related costs in excess of funding as outlined on Slide 18 and impact on the home health care segment of CEWS received in Q1 2021 of \$9.7M (\$nil in Q1 2020)

(2) ADV excludes B.C. contracts expired at the end of January 2020